Faith and community leaders gathered in Springfield on Wednesday to call for increased oversight and transparency in the ...

The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more ...

The House Energy and Commerce Committee has advanced legislation that would have major impacts on payments in the 340B drug discount program, and providers are not pleased with the potential changes.

The federal government is rolling back a pandemic-era waiver that lowered the bar for 340B hospitals to dispense discounted drugs across additional outpatient sites, a decision hospitals said will ...

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

The 340B Program has continued to undergo significant upheaval in 2024 that has the potential to bring about impactful changes to how the 340B Program operates moving forward. These developments have ...

On July 31, 2025, the Department of Health and Human Services (HHS) announced a much-anticipated 340B Rebate Model Pilot Program (Pilot Program) via guidance (Guidance) that will be formally published ...

One of the critical components for Mainers as they navigate the medical quagmire of insurance, providers and treatment is obtaining effective and safe drugs. Cancer treatment is often a long, taxing ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Sen. Peter Welch (D-Vt.) has introduced a bill that would ban pharmaceutical companies from restricting access to 340B drug pricing program discounts, according to a Sept. 11 press release shared with ...

There are no requirements that hospitals pass discounts on to any patients, let alone the underserved. | Opinion ...

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...